BioStock: Spago Nanomedical’s CDO is in place

Recently, First North-listed, Spago Nanomedical announced the recruitment of Paul Hargreaves as Chief Development Officer to oversee the company’s clinical development, with a particular focus on the Tumorad project and the leading candidate drug SN201. BioStock contacted Hargreaves to hear about his background, the new role and his expectations on the task ahead.

Read the interview with Spago Nanomedical's CDO Paul Hargreaves at biostock.se:

https://www.biostock.se/en/2021/10/spago-nanomedicals-cdo-is-in-place/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se